Corrine Savill, Chief Business Officer at Cullinan Oncology, Inc. (CGEM), sold 40,000 shares at $14.09 ($564K) on 2024-01-29, disclosed to the SEC on 2024-01-30.
Scheduled sale ($564k) by Chief Business Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CGEM | SELL | 2022-07-21 | $607K | — | Filing → |
| CGEM | SELL | 2022-07-12 | $533K | — | Filing → |